EN
SINOVAC Trivalent Influenza Vaccine Approved for Use From 6 Months of Age
BEIJING, October 30, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the National Medical Products Administration (NMPA) has approved a supplemental application for its trivalent influenza vaccine, Anflu® (0.5mL/dose), expanding its indication to include infants and young children aged 6 to 35 months. With this approval, the indication for Anflu® now covers all populations aged 6 months and older.
Launched in 2006, Anflu® was the first preservative-free trivalent influenza vaccine marketed in China. This latest age expansion follows the recent approval of SINOVAC's quadrivalent influenza vaccine (0.5mL/dose) for the same age group. This development aligns the dosage and administration of SINOVAC's seasonal influenza portfolio, providing robust immunization protection for the broader population, including highly vulnerable infants and young children of 6 to 35 months.
Beyond the mainland China market, SINOVAC's influenza vaccines have received regulatory approvals in other jurisdictions. In May 2025, both the trivalent and quadrivalent influenza vaccines were approved for registration in the Hong Kong Special Administrative Region, where they are currently the only domestically produced seasonal influenza vaccines approved for use. Internationally, SINOVAC influenza vaccines have been supplied to nearly 20 countries and regions. In Chile, SINOVAC supplied influenza vaccines for the country's publicly funded 2025 national immunization program, under which more than 7.8 million people had been vaccinated by October.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.